| 摘要 |
The present disclosure is directed to methods of administering RLIP76 or an active fragment thereof more than 24 hours after radiation exposure, wherein administration is effective for the protection and treatment of mammals exposed to radiation. In addition, compositions are disclosed including RLIP76 and other radioprotective agents, for example antioxidants. |
